Zhongtai Securities released a research report on April 23 stating that it gave Dian Diagnosis (300244.SZ) a purchase rating. The main reasons for the rating include: 1) 81.90% decrease compared to the ratio; 2) fixed cost amortization, accounts receivable impairment, etc. affect short-term profitability; 3) smooth COVID-19 payables and continued healthy operating cash flow; 4) routine ICL recovery is good, and high-quality development strategies for diagnostic services continue to be deepened; 5) disease solution upgrades and iterations, precision centers, cooperation and co-construction have borne fruit; 6) new technologies and platforms have accelerated transformation, and AD and other features are gradually being implemented. (Mainichi Keizai Shimbun)
中泰证券4月23日发布研报称，给予迪安诊断（300244.SZ）买入评级。评级理由主要包括：1）比下降81.90%；2）固定成本摊销、应收账款减值等影响短期盈利能力；3）新冠应收回款顺畅，经营性现金流持续健康；4）常规ICL恢复良好，诊断服务高质量发展战略持续纵深；5）疾病解决方案升级迭代，精准中心、合作共建再结硕果；6）新技术、新平台加速转换，AD等特色自产品逐渐落地。（每日经济新闻）
Zhongtai Securities released a research report on April 23 stating that it gave Dian Diagnosis (300244.SZ) a purchase rating. The main reasons for the rating include: 1) 81.90% decrease compared to the ratio; 2) fixed cost amortization, accounts receivabl
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.